{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:18:20Z","timestamp":1788200300704,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13300-021-01092-0","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T11:02:32Z","timestamp":1623495752000},"page":"1979-1992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study"],"prefix":"10.1007","volume":"12","author":[{"given":"Abdullah M.","family":"Alguwaihes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,12]]},"reference":[{"key":"1092_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","volume":"128","author":"K Ogurtsova","year":"2017","unstructured":"Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40\u201350.","journal-title":"Diabetes Res Clin Pract"},{"key":"1092_CR2","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2019","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation; 2019.","edition":"9"},{"key":"1092_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/oxfordjournals.aje.a009728","volume":"149","author":"JP Boyle","year":"1999","unstructured":"Boyle JP, Engelgau MM, Thompson TJ, et al. Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus. Am J Epidemiol. 1999;149:55\u201363.","journal-title":"Am J Epidemiol"},{"key":"1092_CR4","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.2337\/diacare.28.11.2613","volume":"28","author":"G Bruno","year":"2005","unstructured":"Bruno G, Runzo C, Cavallo-Perin P, et al. Incidence of type 1 and type 2 diabetes in adults aged 30\u201349 years. Diabetes Care. 2005;28:2613\u20139.","journal-title":"Diabetes Care"},{"key":"1092_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1046\/j.1464-5491.2000.00309.x","volume":"17","author":"JM Evans","year":"2000","unstructured":"Evans JM, Newton RW, Ruta DA, MacDonald TM, Morris AD. Socio-economic status, obesity and prevalence of type 1 and type 2 diabetes mellitus. Diabet Med. 2000;17:478\u201380.","journal-title":"Diabet Med"},{"key":"1092_CR6","volume-title":"Global status report on noncommunicable diseases 2014: attaining the nine global noncommunicable diseases targets; a shared responsibility","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Global status report on noncommunicable diseases 2014: attaining the nine global noncommunicable diseases targets; a shared responsibility. Geneva: World Health Organization; 2014."},{"key":"1092_CR7","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"VL Roger","year":"2011","unstructured":"Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association. Circulation. 2011;123:e18\u2013209.","journal-title":"Circulation"},{"key":"1092_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.298.7.765","volume":"298","author":"SM Donahoe","year":"2007","unstructured":"Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765\u201375.","journal-title":"JAMA"},{"key":"1092_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jchf.2016.08.001","volume":"4","author":"FS Ahmad","year":"2016","unstructured":"Ahmad FS, Ning H, Rich JD, Yancy CW, Lloyd-Jones DM, Wilkins JT. Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project. JACC Heart Fail. 2016;4:911\u20139.","journal-title":"JACC Heart Fail"},{"key":"1092_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1056\/NEJM199910073411506","volume":"341","author":"E Ritz","year":"1999","unstructured":"Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127\u201333.","journal-title":"N Engl J Med"},{"key":"1092_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med"},{"key":"1092_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"MJ Lean","year":"2018","unstructured":"Lean MJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541\u201351.","journal-title":"Lancet"},{"key":"1092_CR13","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1001\/jama.2011.576","volume":"305","author":"D Umpierre","year":"2011","unstructured":"Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305:1790\u20139.","journal-title":"JAMA"},{"key":"1092_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc16-0236","volume":"39","author":"F Rubino","year":"2016","unstructured":"Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by International Diabetes Organizations. Diabetes Care. 2016;39:861\u201377.","journal-title":"Diabetes Care"},{"key":"1092_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1092_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1092_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1092_CR18","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1092_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"1092_CR20","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.2337\/dc20-S001","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 1. Improving care and promoting health in populations: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(1):S7\u201313.","journal-title":"Diabetes Care"},{"key":"1092_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and America College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr Pract. 2020;26:107\u201339.","journal-title":"Endocr Pract"},{"key":"1092_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323.","journal-title":"Eur Heart J"},{"key":"1092_CR23","unstructured":"DeSantis Anthony. Sodium-glucose co-transporter 2 inhibitors for the treatment of type 2 diabetes mellitus. In: Nathan DM, Mulder JE, eds. UpToDate. Waltham (MA): UpToDate; 2020. http:\/\/www.uptodate.com. Accessed 24 Oct 2020."},{"key":"1092_CR24","unstructured":"European Medicines Agency. Forxiga (dapagliflozin) An overview of Forxiga and why it is authorised in the EU. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/forxiga-epar-medicine-overview_en.pdf. Accessed 25 Oct 2020."},{"key":"1092_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1092_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney Disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1092_CR27","doi-asserted-by":"publisher","first-page":"e001007","DOI":"10.1136\/bmjopen-2012-001007","volume":"2","author":"C Clar","year":"2012","unstructured":"Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2:e001007.","journal-title":"BMJ Open"},{"key":"1092_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","volume":"173","author":"A Douros","year":"2020","unstructured":"Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020;173:417\u201325.","journal-title":"Ann Intern Med"},{"key":"1092_CR29","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"1092_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.","journal-title":"BMC Med"},{"key":"1092_CR31","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","volume":"28","author":"P Nyirjesy","year":"2012","unstructured":"Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28:1173\u20138.","journal-title":"Curr Med Res Opin"},{"key":"1092_CR32","first-page":"210","volume":"3","author":"AM Alguwaihes","year":"2020","unstructured":"Alguwaihes AM. Baseline characteristics of patients with type 2 diabetes mellitus initiating Dapagliflozin in Saudi Arabia: results from postauthorization safety study. J Nat Sci Med. 2020;3:210\u20133.","journal-title":"J Nat Sci Med"},{"key":"1092_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/DMSO.S90662","volume":"8","author":"J Seufert","year":"2015","unstructured":"Seufert J. SGLT2 inhibitors\u2014an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015;8:543\u201354.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1092_CR34","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc10-0612","volume":"33","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217\u201324.","journal-title":"Diabetes Care"},{"key":"1092_CR35","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","volume":"13","author":"K Strojek","year":"2011","unstructured":"Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of Dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928\u201338.","journal-title":"Diabetes Obes Metab"},{"key":"1092_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2011.560181","volume":"44","author":"G Musso","year":"2012","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375\u201393.","journal-title":"Ann Med"},{"key":"1092_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/dmrr.2479","volume":"30","author":"M Zhang","year":"2014","unstructured":"Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204\u201321.","journal-title":"Diabetes Metab Res Rev"},{"key":"1092_CR38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with Dapagliflozin. J Diabetes Complicat. 2013;27:473\u20138.","journal-title":"J Diabetes Complicat"},{"key":"1092_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40264-014-0213-4","volume":"37","author":"A Ptaszynska","year":"2014","unstructured":"Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety profile of Dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37:815\u201329.","journal-title":"Drug Saf"},{"key":"1092_CR40","unstructured":"U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015. https:\/\/www.fda.gov\/files\/drugs\/published\/FDA-revises-labels-of-SGLT2-inhibitors-for-diabetes-to-include-warnings-about-too-much-acid-in-the-blood-and-serious-urinary-tract-infections.pdf. Accessed 24 Oct 2020."},{"key":"1092_CR41","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/dom.13124","volume":"20","author":"S Jabbour","year":"2018","unstructured":"Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials. Diabetes Obes Metab. 2018;20:620\u20138.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01092-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01092-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01092-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T04:22:51Z","timestamp":1625718171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01092-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,12]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01092-0","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,12]]},"assertion":[{"value":"18 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}